ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Improving Bone Mineral Density: Risedronate vs. Denosumab

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2022

Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2021bone mineral density (BMD)denosumabGlucocorticoidsOsteoporosisrisedronate

Another Way: RheumMadness 2022 DECT in Gout Scouting Report

MedStar Georgetown Washington Hospital Center: Leen Al Saleh, MD; Ajita Acharya, MD; Elena Obreja, MD; & Akrithi U. Garren, MD  |  February 14, 2022

Research has found dual-energy computed tomography (DECT) may be a non-invasive and cost-effective option to help rheumatologists more accurately diagnose gout.

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:AIartificial intelligenceDECTdual-energy computed tomography (DECT)Goutimagingmachine learning

Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

Nam D. Nguyen, DO (Maj., USAF, MC), Erica Hill, DO (Lt. Col., USAF, MC), & Jay Higgs, MD (Col. [ret], USAF, MC)  |  November 14, 2021

Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

Filed under:ConditionsRheumatoid Arthritis Tagged with:large granular lymphocyte leukemiavertebral fracture

Standing on a Hidden Burden: The Oft-Overlooked Problem of Foot and Ankle Osteoarthritis

Standing on a Hidden Burden: The Oft-Overlooked Problem of Foot and Ankle Osteoarthritis

Kade L. Paterson, PhD, BPod, BAppSci(Hons), Marian T. Hannan, DSc, MPH, Lara Chapman, MSc, BPod, Edward Roddy, DM, FRCP, Hylton B. Menz, PhD, BPod, & Catherine Bowen, PhD, BPod  |  November 14, 2021

The high prevalence and significant burden of osteoarthritis (OA) are well known. But it’s becoming apparent that OA research efforts don’t necessarily match disease prevalence or disability. The International Foot and Ankle Osteoarthritis Consortium (IFOAC) is an international organization of volunteers that seeks to highlight a major and often overlooked problem in OA research—foot and…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:International Foot and Ankle Osteoarthritis Consortium (IFOAC)

Gout FocusRheum expanded abstract sample

Gout is a common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. The good news: The etiology of gout is well understood, and effective, inexpensive medications exist to treat it. However, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and…

Case Report: Reactive Arthritis Following COVID-19

Samuel C. Purkey, DO, James Z. Drew, MD, & Marcum Collins, MD  |  September 14, 2021

SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…

Filed under:Conditions Tagged with:COVID-19Reactive arthritisTenosynovitis

Untangling the Diagnosis & Management of GCA

Jason Liebowitz, MD, FACR  |  June 28, 2021

Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsVasculitis Tagged with:EULARGCAgiant cell arteritis (GCA)vision loss

Bipartisan DXA Bill Under Consideration in Congress

From the College  |  June 21, 2021

The Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act would set a $98 floor for Medicare reimbursement for the dual-energy X-ray absorptiometry (DXA) bone density test.

Filed under:Billing/CodingLegislation & Advocacy Tagged with:dual-energy X-ray absorptiometry (DXA)Legislation & AdvocacyMedicare reimbursement rate

The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab

Michele B. Kaufman, PharmD, BCGP  |  May 24, 2021

As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsdenosumabEB1001monoclonal antibody

4 ARP Members Talk About Their Roads to Advocacy & Why It Matters

From ARP Representatives to the ACR Government Affairs Committee  |  May 13, 2021

The Budget Control Act of 2011 cut Medicare physician payments by 2% across the board. The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law in 2020, suspended this sequester (i.e., a cut in government spending) between May 1 and Dec. 31, 2020. In the Consolidated Appropriations Act, signed into law in December…

Filed under:Interprofessional PerspectiveLegislation & Advocacy Tagged with:Association of Rheumatology Professionals (ARP)

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences